Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

Onvansertib cut the risk of death or disease progression by 62% versus standard of care, but analysts await more detailed ...

Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just ...

BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding ...

The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which ...

Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric ...

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...

In life sciences manufacturing, inspections by the FDA, state regulators or other agencies are part of the job. But too often ...

Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the ...